Replies to post #75230 on Decision Diagnostics Corp (DECN)

[IPwatcher]

Your understanding is correct.
Antibody testing is imperfect.
But it potentially has some value for population screening and identifying levels of immunity. And it will work in blood.

For current infection and infectivity, PCR swabs from the upper respiratory tracts is the only thing that works reliably at present.
DECN at present have mothing that can or ever will compete with that.

So a labelled immunoassay approach would be the best approach for a company like DECN to take (and to have taken).

But they are late to the party and behind the herd, as ever!
DECN do not have an antibody test, or even an established methodology ready to roll.
Others do.
And this is not a diagnostic area where DECNs historical expertise is established.